NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Enterprise Value: -15.65M for April 5, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 05, 2024 | -15.65M |
| April 04, 2024 | -15.65M |
| April 03, 2024 | -13.98M |
| April 02, 2024 | -13.98M |
| April 01, 2024 | -13.98M |
| March 28, 2024 | -11.48M |
| March 27, 2024 | -8.976M |
| March 26, 2024 | -14.82M |
| March 25, 2024 | -14.82M |
| March 22, 2024 | -14.82M |
| March 21, 2024 | -13.98M |
| March 20, 2024 | -14.82M |
| March 19, 2024 | -13.98M |
| March 18, 2024 | -13.98M |
| March 15, 2024 | -13.15M |
| March 14, 2024 | -16.49M |
| March 13, 2024 | -16.49M |
| March 12, 2024 | -15.65M |
| March 11, 2024 | -15.65M |
| March 08, 2024 | -16.49M |
| March 07, 2024 | -16.49M |
| March 06, 2024 | -17.32M |
| March 05, 2024 | -16.49M |
| March 04, 2024 | -17.32M |
| March 01, 2024 | -17.32M |
| Date | Value |
|---|---|
| February 29, 2024 | -17.32M |
| February 28, 2024 | -16.49M |
| February 27, 2024 | -8.141M |
| February 26, 2024 | -16.90M |
| February 23, 2024 | 15.23M |
| February 22, 2024 | 15.23M |
| February 21, 2024 | 15.00M |
| February 20, 2024 | -10.70M |
| February 16, 2024 | -17.34M |
| February 15, 2024 | -20.65M |
| February 14, 2024 | -22.31M |
| February 13, 2024 | -22.31M |
| February 12, 2024 | -18.17M |
| February 09, 2024 | -18.17M |
| February 08, 2024 | -25.63M |
| February 07, 2024 | -25.63M |
| February 06, 2024 | -26.46M |
| February 05, 2024 | -28.94M |
| February 02, 2024 | -24.80M |
| February 01, 2024 | -20.65M |
| January 31, 2024 | -17.34M |
| January 30, 2024 | -15.68M |
| January 29, 2024 | -16.51M |
| January 26, 2024 | -20.65M |
| January 25, 2024 | -28.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-116.39M
Minimum
Nov 17 2023
2.154B
Maximum
Mar 17 2021
708.89M
Average
787.69M
Median
Jun 23 2022
Enterprise Value Benchmarks
| Catalent Inc | 14.98B |
| AIM ImmunoTech Inc | 11.80M |
| Perspective Therapeutics Inc | 464.87M |
| Protalix BioTherapeutics Inc | 66.51M |
| Armata Pharmaceuticals Inc | 194.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.67M |
| Revenue (Quarterly) | 0.165M |
| Total Expenses (Quarterly) | 29.83M |
| EPS Diluted (Quarterly) | -0.34 |
| Profit Margin (Quarterly) | -16.77K% |
| Earnings Yield | -112.3% |
| Normalized Earnings Yield | -112.34 |